{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T03:52:42Z","timestamp":1754020362127,"version":"3.40.3"},"publisher-location":"Dordrecht","reference-count":47,"publisher":"Springer Netherlands","isbn-type":[{"type":"print","value":"9789401772143"},{"type":"electronic","value":"9789401772150"}],"license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015]]},"DOI":"10.1007\/978-94-017-7215-0_19","type":"book-chapter","created":{"date-parts":[[2015,11,3]],"date-time":"2015-11-03T07:05:41Z","timestamp":1446534341000},"page":"317-323","source":"Crossref","is-referenced-by-count":5,"title":["A Critical Approach to Clinical Biochemistry of Chromogranin A"],"prefix":"10.1007","author":[{"given":"Patrizia","family":"Bottoni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"De Michele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Scatena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"19_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/bj2620001","volume":"262","author":"JP Simon","year":"1989","unstructured":"Simon JP, Aunis D (1989) Biochemistry of the chromogranin A protein family. Biochem J 262:1\u201313","journal-title":"Biochem J"},{"key":"19_CR2","doi-asserted-by":"crossref","unstructured":"Sokoll LJ, Rai AJ, Chan DW (2012) Tumor markers. In: Burtis CA, Ashwood ER, Bruns DE (eds) Tietz textbook of clinical chemistry and molecular diagnostics. Elsevier-Saunders, St.Louis, p 650","DOI":"10.1016\/B978-1-4160-6164-9.00024-X"},{"key":"19_CR3","doi-asserted-by":"publisher","first-page":"R45","DOI":"10.1530\/EC-14-0027","volume":"3","author":"MA D\u2019Amico","year":"2014","unstructured":"D\u2019Amico MA, Ghinassi B, Izzicupo P, Manzoli L, Di Baldassarre A (2014) Biological function and clinical relevance of chromogranin A and derived peptides. Endocr Connect 3:R45\u2013R54","journal-title":"Endocr Connect"},{"key":"19_CR4","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1210\/er.2010-0027","volume":"32","author":"A Bartolomucci","year":"2011","unstructured":"Bartolomucci A, Possenti R, Mahata SK et al (2011) The extended granin family: structure, function, and biomedical implications. Endocr Rev 32:755\u2013797","journal-title":"Endocr Rev"},{"key":"19_CR5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/B978-0-12-411512-5.00005-1","volume":"68","author":"R Borges","year":"2013","unstructured":"Borges R, Dominguez N, Smith CB, Bandyopadhyay GK, O\u2019Connor DT, Mahata SK, Bartolomucci A (2013) Granins and catecholamines: functional interaction in chromaffin cells and adipose tissue. Adv Pharmacol 68:93\u2013113","journal-title":"Adv Pharmacol"},{"key":"19_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/0-306-46837-9_3","volume":"482","author":"HH Gerdes","year":"2000","unstructured":"Gerdes HH, Glombik MM (2000) Signal-mediated sorting of chromogranins to secretory granules. Adv Exp Med Biol 482:41\u201354","journal-title":"Adv Exp Med Biol"},{"key":"19_CR7","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/0-306-46837-9_2","volume":"482","author":"D Aunis","year":"2000","unstructured":"Aunis D, Metz-Boutigue MH (2000) Chromogranins: current concepts. Structural and functional aspects. Adv Exp Med Biol 482:21\u201338","journal-title":"Adv Exp Med Biol"},{"key":"19_CR8","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1016\/j.neurobiolaging.2013.05.018","volume":"34","author":"Z Wu","year":"2013","unstructured":"Wu Z, Sun L, Hashioka S, Yu S, Schwab C, Okada R, Hayashi Y, McGeer PL, Nakanishi H (2013) Differential pathways for interleukin-1\u03b2 production activated by chromogranin A and amyloid \u03b2 in microglia. Neurobiol Aging 34:2715\u20132725","journal-title":"Neurobiol Aging"},{"key":"19_CR9","doi-asserted-by":"publisher","first-page":"E21","DOI":"10.1503\/jpn.120170","volume":"38","author":"J Jakobsson","year":"2013","unstructured":"Jakobsson J, Stridsberg M, Zetterberg H, Blennow K, Ekman CJ, Johansson AG, Sellgren C, Land\u00e9n M (2013) Decreased cerebrospinal fluid secretogranin II concentrations in severe forms of bipolar disorder. J Psychiatry Neurosci 38:E21\u2013E26","journal-title":"J Psychiatry Neurosci"},{"key":"19_CR10","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/j.1750-3639.2012.00644.x","volume":"23","author":"V Pl\u00e1","year":"2013","unstructured":"Pl\u00e1 V, Paco S, Ghezali G, Ciria V, Pozas E, Ferrer I, Aguado F (2013) Secretory sorting receptors carboxypeptidase E and secretogranin III in amyloid \u03b2-associated neural degeneration in Alzheimer\u2019s disease. Brain Pathol 23:274\u2013284","journal-title":"Brain Pathol"},{"key":"19_CR11","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.psyneuen.2010.12.018","volume":"36","author":"PC Guest","year":"2011","unstructured":"Guest PC, Schwarz E, Krishnamurthy D, Harris LW, Leweke FM, Rothermundt M, van Beveren NJ, Spain M, Barnes A, Steiner J, Rahmoune H, Bahn S (2011) Altered levels of circulating insulin and other neuroendocrine hormones associated with the onset of schizophrenia. Psychoneuroendocrinology 36:1092\u20131096","journal-title":"Psychoneuroendocrinology"},{"key":"19_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S2213-8587(13)70035-4","volume":"1","author":"JP Goetze","year":"2013","unstructured":"Goetze JP, Alehagen U, Flyvbjerg A, Rehfeld JF (2013) Making sense of chromogranin A in heart disease. Lancet Diab Endocrinol 1:7\u20138","journal-title":"Lancet Diab Endocrinol"},{"key":"19_CR13","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2217\/bmm.13.102","volume":"8","author":"JP Goetze","year":"2014","unstructured":"Goetze JP, Alehagen U, Flyvbjerg A, Rehfeld JF (2014) Chromogranin A as a biomarker in cardiovascular disease. Biomark Med 8:133\u2013140","journal-title":"Biomark Med"},{"key":"19_CR14","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.jacc.2009.11.064","volume":"55","author":"K Zhang","year":"2010","unstructured":"Zhang K, Rao F, Wang L, Rana BK, Ghosh S, Mahata M, Salem RM, Rodriguez-Flores JL, Fung MM, Waalen J, Tayo B, Taupenot L, Mahata SK, O\u2019Connor DT (2010) Common functional genetic variants in catecholamine storage vesicle protein promoter motifs interact to trigger systemic hypertension. J Am Coll Cardiol 55:1463\u20131475","journal-title":"J Am Coll Cardiol"},{"key":"19_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3109\/08860220903377597","volume":"32","author":"L Yu","year":"2010","unstructured":"Yu L, Jiang L, Zhou XJ, Zhu L, Zhang H (2010) Common genetic variants in the chromogranin a promoter are associated with renal injury in IgA nephropathy patients with malignant hypertension. Ren Fail 32:41\u201346","journal-title":"Ren Fail"},{"key":"19_CR16","first-page":"175","volume":"30","author":"JT Wu","year":"2000","unstructured":"Wu JT, Erickson AJ, Tsao KC, Wu TL, Sun CF (2000) Elevated serum chromogranin A is detectable in patients with carcinomas at advanced disease stages. Ann Clin Lab Sci 30:175\u2013178","journal-title":"Ann Clin Lab Sci"},{"key":"19_CR17","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.eururo.2013.04.020","volume":"64","author":"A Sciarra","year":"2013","unstructured":"Sciarra A, Abrahamsson PA, Brausi M, Galsky M, Mottet N, Sartor O, Tammela TL, Calais da Silva F (2013) Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials. Eur Urol 64:722\u2013730","journal-title":"Eur Urol"},{"key":"19_CR18","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/pros.10222","volume":"55","author":"A Sciarra","year":"2003","unstructured":"Sciarra A, Monti S, Gentile V, Mariotti G, Cardi A, Voria G, Lucera R, Di Silverio F (2003) Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma. Prostate 55:168\u2013179","journal-title":"Prostate"},{"key":"19_CR19","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3747\/co.v17i3.484","volume":"17","author":"W Kocha","year":"2010","unstructured":"Kocha W, Maroun J, Kennecke H, Law C, Metrakos P, Ouellet JF, Reid R, Rowsell C, Shah A, Singh S, Van Uum S, Wong R (2010) Consensus recommendations for the diagnosis and management of well-differentiated gastroenterohepatic neuroendocrine tumours: a revised statement from a Canadian National Expert Group. Curr Oncol 17:49\u201364","journal-title":"Curr Oncol"},{"key":"19_CR20","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s40618-014-0119-0","volume":"37","author":"F Grimaldi","year":"2014","unstructured":"Grimaldi F, Fazio N, Attanasio R, Frasoldati A, Papini E, Angelini F, Baldelli R, Berretti D, Bianchetti S, Bizzarri G, Caputo M, Castello R, Cremonini N, Crescenzi A, Dav\u00ec MV, D\u2019Elia AV, Faggiano A, Pizzolitto S, Versari A, Zini M, Rindi G, Oberg K (2014) Italian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms. J Endocrinol Invest 37:875\u2013909","journal-title":"J Endocrinol Invest"},{"key":"19_CR21","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1097\/MPA.0b013e3181ebb2a5","volume":"39","author":"JP Boudreaux","year":"2010","unstructured":"Boudreaux JP, Klimstra DS, Hassan MM et al (2010) The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors-well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum. Pancreas 39:753\u2013766","journal-title":"Pancreas"},{"key":"19_CR22","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1097\/MPA.0b013e3181ec1261","volume":"39","author":"LB Anthony","year":"2010","unstructured":"Anthony LB, Stosberg JR, Klimstra DS et al (2010) The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors \u2013 well-differentiated NETs of the distal colon and rectum. Pancreas 39:767\u2013774","journal-title":"Pancreas"},{"key":"19_CR23","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1210\/jc.2007-1354","volume":"93","author":"A Algeciras-Schimnich","year":"2008","unstructured":"Algeciras-Schimnich A, Preissner CM, Young WF et al (2008) Plasma chromogranin A or urine fractionated metanephrines follow-up testing improves the diagnostic accuracy of plasma fractionated metanephrines for pheochromocytomas. J Clin Endocrinol Metab 93:91\u201395","journal-title":"J Clin Endocrinol Metab"},{"key":"19_CR24","unstructured":"Kullke MH, Benson AB, Bergsland E et al (2012) National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines): NCCN Guidelines version 1.2012 \u2013 neuroendocrine tumors, pp 1\u201394, E-Pub Date 20 Mar 2012. URL: http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/neuroendocrine.pdf"},{"key":"19_CR25","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1530\/EC-13-0052","volume":"2","author":"RC van Adrichem","year":"2013","unstructured":"van Adrichem RC, Hofland LJ, Feelders RA, De Martino MC, van Koetsveld PM, van Eijck CH, de Krijger RR, Sprij-Mooij DM, Janssen JA, de Herder WW (2013) Chromogranin A, Ki-67 index and IGF-related genes in patients with neuroendocrine tumors. Endocr Connect 2:172\u2013177","journal-title":"Endocr Connect"},{"key":"19_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076462","volume":"8","author":"AR Moore","year":"2013","unstructured":"Moore AR, Boyce M, Steele IA, Campbell F, Varro A, Pritchard DM (2013) Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis. PLoS One 8, e76462","journal-title":"PLoS One"},{"key":"19_CR27","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s10637-012-9910-y","volume":"31","author":"T Ito","year":"2013","unstructured":"Ito T, Okusaka T, Nishida T, Yamao K, Igarashi H, Morizane C, Kondo S, Mizuno N, Hara K, Sawaki A, Hashigaki S, Kimura N, Murakami M, Ohki E, Chao RC, Imamura M (2013) Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor. Invest New Drugs 31:1265\u20131274","journal-title":"Invest New Drugs"},{"key":"19_CR28","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1530\/ERC-11-0144","volume":"18","author":"C Kratochwil","year":"2011","unstructured":"Kratochwil C, L\u00f3pez-Ben\u00edtez R, Mier W, Haufe S, Isermann B, Kauczor HU, Choyke PL, Haberkorn U, Giesel FL (2011) Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastases. Endocr Relat Cancer 18:595\u2013602","journal-title":"Endocr Relat Cancer"},{"key":"19_CR29","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1634\/theoncologist.2010-0323","volume":"16","author":"SJ Lubner","year":"2011","unstructured":"Lubner SJ, Kunnimalaiyaan M, Holen KD, Ning L, Ndiaye M, Loconte NK, Mulkerin DL, Schelman WR, Chen H (2011) A preclinical and clinical study of lithium in low-grade neuroendocrine tumors. Oncologist 16:452\u2013457","journal-title":"Oncologist"},{"key":"19_CR30","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000247","volume":"93","author":"YH Wang","year":"2014","unstructured":"Wang YH, Yang QC, Lin Y, Xue L, Chen MH, Chen J (2014) Chromogranin A as a marker for diagnosis, treatment, and survival in patients with gastroenteropancreatic neuroendocrine neoplasm. Medicine 93, e247","journal-title":"Medicine"},{"key":"19_CR31","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1159\/000370007","volume":"31","author":"AP Jilesen","year":"2015","unstructured":"Jilesen AP, Busch OR, van Gulik TM, Gouma DJ, Nieveen van Dijkum EJ (2015) Standard pre- and postoperative determination of chromogranin A in resectable non-functioning pancreatic neuroendocrine tumors \u2013 diagnostic accuracy: NF-pNET and low tumor burden. Dig Surg 31:407\u2013414","journal-title":"Dig Surg"},{"key":"19_CR32","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.1210\/jc.2013-1800","volume":"98","author":"JM de Laat","year":"2013","unstructured":"de Laat JM, Pieterman CR, Weijmans M, Hermus AR, Dekkers OM, de Herder WW, van der Horst-Schrivers AN, Drent ML, Bisschop PH, Havekes B, Vriens MR, Valk GD (2013) Low accuracy of tumor markers for diagnosing pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1 patients. J Clin Endocrinol Metab 98:4143\u20134151","journal-title":"J Clin Endocrinol Metab"},{"key":"19_CR33","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/1472-6823-14-64","volume":"14","author":"XW Qiao","year":"2014","unstructured":"Qiao XW, Qiu L, Chen YJ, Meng CT, Sun Z, Bai CM, Zhao DC, Zhang TP, Zhao YP, Song YL, Wang YH, Chen J, Lu CM (2014) Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas. BMC Endocr Disord 14:64","journal-title":"BMC Endocr Disord"},{"key":"19_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0088698","volume":"9","author":"J Guillemot","year":"2014","unstructured":"Guillemot J, Gu\u00e9rin M, Thou\u00ebnnon E, Mont\u00e9ro-Hadjadje M, Leprince J, Lefebvre H, Klein M, Muresan M, Anouar Y, Yon L (2014) Characterization and plasma measurement of the WE-14 peptide in patients with pheochromocytoma. PLoS One 9, e88698","journal-title":"PLoS One"},{"key":"19_CR35","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/S0022-5347(01)69075-X","volume":"167","author":"S Isshiki","year":"2002","unstructured":"Isshiki S, Akakura K, Komiya A, Suzuki H, Kamiya N, Ito H (2002) Chromogranin aconcentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer. J Urol 167:512\u2013515","journal-title":"J Urol"},{"key":"19_CR36","doi-asserted-by":"publisher","first-page":"3943","DOI":"10.1158\/1078-0432.CCR-03-0200","volume":"10","author":"JV Tricoli","year":"2004","unstructured":"Tricoli JV, Schoenfeldt M, Conley BA (2004) Detection of prostate cancer and predicting progression: current and future diagnostic markers. Clin Cancer Res 10:3943\u20133953","journal-title":"Clin Cancer Res"},{"key":"19_CR37","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1046\/j.1464-4096.2001.001223.x","volume":"88","author":"M Ferrero-Po\u00fcs","year":"2001","unstructured":"Ferrero-Po\u00fcs M, Hersant AM, Pecking A, Br\u00e9sard-Leroy M, Pichon MF (2001) Serum chromogranin-A in advanced prostate cancer. BJU Int 88:790\u2013796","journal-title":"BJU Int"},{"key":"19_CR38","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3109\/21681805.2014.905633","volume":"48","author":"D Hirano","year":"2014","unstructured":"Hirano D, Hasegawa R, Satoh K, Mochida J, Yamanaka Y, Hirakata H, Yamaguchi K, Sugimoto S, Kawata N, Takahashi S (2014) Prospective study on the relationship between clinical efficacy of secondary hormone therapy with flutamide and neuroendocrine differentiation in patients with relapsed prostate cancer after first line hormone therapy. Scand J Urol 48:436\u2013444","journal-title":"Scand J Urol"},{"key":"19_CR39","first-page":"2525","volume":"22","author":"M Tarle","year":"2002","unstructured":"Tarle M, Ahel MZ, Kovaci\u0107 K (2002) Acquired neuroendocrine-positivity during maximal androgen blockade in prostate cancer patients. Anticancer Res 22:2525\u20132529","journal-title":"Anticancer Res"},{"key":"19_CR40","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1097\/GIM.0b013e318216cc6d","volume":"13","author":"J Moline","year":"2011","unstructured":"Moline J, Eng C (2011) Multiple endocrine neoplasia type 2: an overview. Genet Med 13:755\u2013764","journal-title":"Genet Med"},{"key":"19_CR41","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/cen.12513","volume":"81","author":"D Ta\u00efeb","year":"2014","unstructured":"Ta\u00efeb D, Kebebew E, Castinetti F, Chen CC, Henry JF, Pacak K (2014) Diagnosis and preoperative imaging of multiple endocrine neoplasia type 2: current status and future directions. Clin Endocrinol (Oxf) 81:317\u2013328","journal-title":"Clin Endocrinol (Oxf)"},{"key":"19_CR42","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1373\/clinchem.2011.176099","volume":"58","author":"PR Bech","year":"2012","unstructured":"Bech PR, Ramachandran R, Dhillo WS et al (2012) Quantifying the effects of renal impairment on plasma concentrations of the neuroendocrine neoplasia biomarkers chromogranin A, chromogranin B, and cocaine- and amphetamine-regulated transcript. Clin Chem 58:941\u2013943","journal-title":"Clin Chem"},{"key":"19_CR43","first-page":"1139","volume":"78","author":"MP Canale","year":"1994","unstructured":"Canale MP, Bravo EL (1994) Diagnostic specificity of serum chromogranin-A for pheochromocytoma in patients with renal dysfunction. J Clin Endocrinol Metab 78:1139\u20131144","journal-title":"J Clin Endocrinol Metab"},{"key":"19_CR44","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/bjc.2011.380","volume":"32","author":"CM Korse","year":"2011","unstructured":"Korse CM, Muller M, Taal BG (2011) Discontinuation of proton pump inhibitors during assessment of chromogranin A levels in patients with neuroendocrine tumors. Br J Cancer 32:1173\u20131175","journal-title":"Br J Cancer"},{"key":"19_CR45","doi-asserted-by":"crossref","unstructured":"Mosli HH, Dennis A, Kosha W, Asher LJ, Van Uum SH (2012) Effect of short-term proton pump inhibitor treatment and its discontinuation on chromogranin A in healthy subjects. J Clin Endocrinol Metab 97:E1731\u2013E1735","DOI":"10.1210\/jc.2012-1548"},{"key":"19_CR46","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/cen.12088","volume":"79","author":"P Glinicki","year":"2013","unstructured":"Glinicki P, Kapu\u015bci\u0144ska R, Jeske W (2013) Improved diagnostic accuracy for neuroendocrine neoplasms using two chromogranin A assays: the importance of protein matrix effects. Clin Endocrinol (Oxf) 79:295\u2013296","journal-title":"Clin Endocrinol (Oxf)"},{"key":"19_CR47","doi-asserted-by":"publisher","first-page":"e132","DOI":"10.5301\/jbm.5000096","volume":"30","author":"D Gruson","year":"2015","unstructured":"Gruson D, Lepoutre T, Smits F (2015) Chromogranin-A levels measured with automated immunoassay. Int J Biol Markers 30:e132\u2013e135","journal-title":"Int J Biol Markers"}],"container-title":["Advances in Experimental Medicine and Biology","Advances in Cancer Biomarkers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-94-017-7215-0_19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T17:33:44Z","timestamp":1676482424000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-94-017-7215-0_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"ISBN":["9789401772143","9789401772150"],"references-count":47,"URL":"https:\/\/doi.org\/10.1007\/978-94-017-7215-0_19","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"type":"print","value":"0065-2598"},{"type":"electronic","value":"2214-8019"}],"subject":[],"published":{"date-parts":[[2015]]}}}